Abstract 11568, Poster 502: Intratumoral INT230-6 (Cisplatin, Vinblastine, Shao) Alone or with Ipilimumab Prolonged Survival with Favorable Safety in Adults with Refractory Sarcomas (NCT 03058289) June 4, 2023
Abstract 573 phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: The INVINCIBLE Trial June 4, 2023
A phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: The INVINCIBLE Trial December 8, 2022
Intratumoral INT230-6 (Cisplatin, Vinblastine, Shao) Alone or with Ipilimumab Prolonged Survival with Favorable Safety in Adults with Refractory Sarcomas (NCT 03058289) November 18, 2022
Safety and survival results from a phase 1/2 trial of intratumoral agent INT230-6 (cisplatin vinblastine) induces immunological cancer cell death alone or with pembrolizumab (PEM) in patients with refractory, metastatic cancers IT-01; Merck KEYNOTE-A10] November 11, 2022
A Phase II Randomized Window of Opportunity Trial Evaluating Cytotoxic and Immunomodulatory effects of Intratumoral INT230-6 (Cisplatin, Vinblastine) in Early-Stage Breast Cancer: the INVINCIBLE Trial November 10, 2022
INT230-6 Demonstrates Activity as Monotherapy and in Combination with Ipilimumab (IPI) Across a Broad Spectrum of Refractory Soft Tissue Sarcomas (STS) [Intensity IT-01; BMS#CA184-592] June 3, 2022
Intratumoral INT230-6 Causes Tumor Necrosis and Promotes a Systemic Immune Response; Results from a Multi-center Phase 1/2 Study of Solid Tumors with and without Pembrolizumab (PEM) [Intensity IT-01; Merck KEYNOTE-A10] June 3, 2022
Intratumoral (IT) INT230-6 Can Cause Tumor Necrosis in vivo: Preliminary Results of a Phase II Randomized Presurgical Window-of-Opportunity Study in Early Breast Cancers (the INVINCIBLE study) – PART I June 3, 2022
Safety and Efficacy of INT230-6, a Potential First-in-Class Intratumoral Therapy, in Monotherapy and in Combination with Pembrolizumab: Results from the IT-01 Study [KEYNOTE-A10] in Subjects with Locally Advanced, Unresectable and Metastatic Breast Cancer December 10, 2021
